Why the study?
Does propranolol improve asymmetrical septal hypertrophy and hypertrophic cardiomyopathy in a neonate born to a diabetic mother?
Does propranolol improve asymmetrical septal hypertrophy and hypertrophic cardiomyopathy in a neonate born to a diabetic mother?
Propranolol successfully treated asymmetrical septal hypertrophy and hypertrophic cardiomyopathy in an infant of a diabetic mother, leading to resolution of hypertrophy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for propranolol in neonatal septal hypertrophy; prospective trials needed before clinical adoption.
Hypertrophic cardiomyopathy (HOCM) that includes thickening of one or both of the ventricular walls, hypertrophy of the interventricular septum; systolic and diastolic dysfunction, transient hypertrophic sub-aortic stenosis is a well-recognized comorbidity in infants of diabetic mothers. This cardiac complication in the infant of the diabetic mother has recently been named as pathological ventricular hypertrophy to avoid confusion with the autosomal dominant form of congenital HCM. We report a neonate that was diagnosed as case of asymmetrical septal hypertrophy and hypertrophic cardiomyopathy and was born to mother who had poor glycemic control and was treated successfully with propranolol and showed resolution of hypertrophy in follow-up echocardiography.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: